NO20031580D0 - Fremgangsmåter for modulering av bl¶refunksjonen - Google Patents

Fremgangsmåter for modulering av bl¶refunksjonen

Info

Publication number
NO20031580D0
NO20031580D0 NO20031580A NO20031580A NO20031580D0 NO 20031580 D0 NO20031580 D0 NO 20031580D0 NO 20031580 A NO20031580 A NO 20031580A NO 20031580 A NO20031580 A NO 20031580A NO 20031580 D0 NO20031580 D0 NO 20031580D0
Authority
NO
Norway
Prior art keywords
modulating
procedures
bleeding function
bleeding
function
Prior art date
Application number
NO20031580A
Other languages
English (en)
Other versions
NO20031580L (no
Inventor
Michael Thomas Argentieri
Howard Jeffrey Sheldon
Robert Mark Bowlby
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26933980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20031580(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20031580D0 publication Critical patent/NO20031580D0/no
Publication of NO20031580L publication Critical patent/NO20031580L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0684Cells of the urinary tract or kidneys
    • C12N5/0686Kidney cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00Use of cells in diagnostics
    • C12N2503/02Drug screening
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/341Urinary incontinence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20031580A 2000-10-17 2003-04-08 Fremgangsmåter for modulering av bl¶refunksjonen NO20031580L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24107800P 2000-10-17 2000-10-17
US28142801P 2001-04-04 2001-04-04
PCT/US2001/032204 WO2002032419A2 (en) 2000-10-17 2001-10-16 Methods for modulating bladder function

Publications (2)

Publication Number Publication Date
NO20031580D0 true NO20031580D0 (no) 2003-04-08
NO20031580L NO20031580L (no) 2003-06-14

Family

ID=26933980

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031580A NO20031580L (no) 2000-10-17 2003-04-08 Fremgangsmåter for modulering av bl¶refunksjonen

Country Status (22)

Country Link
US (3) US6348486B1 (no)
EP (2) EP1326597B1 (no)
JP (2) JP2004511516A (no)
KR (1) KR20030040540A (no)
CN (1) CN1287781C (no)
AR (1) AR030901A1 (no)
AT (1) ATE314061T1 (no)
AU (2) AU2002211758A1 (no)
BR (1) BR0114718A (no)
CA (2) CA2450467C (no)
CY (1) CY1105353T1 (no)
DE (1) DE60116352T2 (no)
DK (1) DK1326597T3 (no)
ES (1) ES2253432T3 (no)
HU (1) HUP0303288A2 (no)
IL (1) IL155090A0 (no)
MX (1) MXPA03003339A (no)
NO (1) NO20031580L (no)
NZ (1) NZ525301A (no)
PL (1) PL360903A1 (no)
TW (1) TWI287984B (no)
WO (2) WO2002032419A2 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
KR20050074493A (ko) * 2002-10-21 2005-07-18 라모트 앳 텔-아비브 유니버시티 리미티드 칼륨 채널 및/또는 피질 뉴우런 작용 조절제로서 유용한n-페닐안트라닐산 및/또는 2-벤즈이미다졸론의 유도체
EP1631546A1 (en) * 2003-04-25 2006-03-08 H. Lundbeck A/S Sustituted indoline and indole derivatives
US20070292528A1 (en) * 2003-05-06 2007-12-20 University Hospital Of Basel Kcnma1 as a Therapeutic Target in Cancer Treatment
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US20060148782A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
DK1530967T3 (da) * 2003-11-13 2006-07-03 Ferring Bv Blisterpakning og dertil hörende fast dosisform
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US7517960B2 (en) 2006-01-19 2009-04-14 Wyeth Rat KCNQ5 voltage-gated potassium channel
SE528446C2 (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
BRPI0716715B1 (pt) * 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CA2670966A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
DE102007012029A1 (de) 2007-03-13 2008-09-18 Grünenthal GmbH Verfahren zur Identifizierung der agonistischen Aktivität einer Zielverbindung auf einen Kaliumkanal
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
JP5451613B2 (ja) 2007-08-06 2014-03-26 アラーガン、インコーポレイテッド デスモプレシン薬物送達のための方法及びデバイス
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US8765815B2 (en) 2007-09-20 2014-07-01 Ramot At Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
NO3085381T3 (no) * 2008-05-21 2018-09-15
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100120906A1 (en) * 2008-07-18 2010-05-13 Valeant Pharmaceuticals International Modified release formulation and methods of use
WO2011101456A2 (en) * 2010-02-19 2011-08-25 Medichem S.A. Stabilized phenylcarbamate derivative in solid state
KR20150053257A (ko) * 2012-04-30 2015-05-15 사이플루어 라이프 사이언시즈, 엘엘씨 플루오르화 2-아미노-4-(벤질아미노)페닐카르바메이트 유도체
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US11358930B2 (en) 2018-04-20 2022-06-14 University of Pittsburgh—of the Commonwealth System of Higher Education Selective potassium channel agonists
BR112022006292A2 (pt) * 2019-10-07 2022-06-28 De Shaw Res Llc Compostos heterobicílicos de arila como bloqueadores de canais de agitador de potássio kv1.3
CN114728177B (zh) * 2019-10-07 2025-06-24 D·E·萧尔研究有限责任公司 作为Kv1.3钾Shaker通道阻滞剂的芳基杂二环化合物
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
WO2021092439A1 (en) 2019-11-08 2021-05-14 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
IL304920A (en) 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia
WO2025233532A1 (en) 2024-05-10 2025-11-13 Les Laboratoires Servier Maxi-k potassium channel openers and therapeutic applications thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37460A (en) * 1863-01-20 Improvement in meat-broilers
GB9220570D0 (en) * 1991-10-21 1992-11-11 Ici Plc Therapeutic agent
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
US6277978B1 (en) * 1995-12-22 2001-08-21 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
JP2001512673A (ja) * 1997-08-12 2001-08-28 ブリストル−マイヤーズ スクイブ カンパニー Kcnqカリウムチャンネルおよびそれの活性調節方法
US6413719B1 (en) * 1997-10-24 2002-07-02 University Of Utah Research Foundation KCNQ2 and KCNQ3-potassium channel genes which are mutated in benign familial neonatal convulsions (BFNC) and other epilepsies
AU2532299A (en) * 1998-02-17 1999-08-30 Astrazeneca Uk Limited Potassium channel polypeptide
US6133275A (en) * 1998-05-06 2000-10-17 Abbott Laboratories 3-phenylpyrrolidine alpha-1 adrenergic compounds
US6794161B1 (en) 1999-01-26 2004-09-21 Neurosearch A/S Potassium channels and genes encoding these potassium channels
AU2092700A (en) * 1999-01-26 2000-08-18 Neurosearch A/S Novel potassium channels and genes encoding these potassium channels
IT1312224B1 (it) * 1999-03-23 2002-04-09 Cit Alcatel Circuito pre/post-distorcitore particolarmente per sistemi aradiofrequenza microonde.
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6617131B2 (en) * 2000-03-21 2003-09-09 Aventis Pharma Deutschland Gmbh Nucleic acid molecule encoding the potassium channel protein, KCNQ5
WO2001075108A1 (en) * 2000-04-03 2001-10-11 Lexicon Genetics Incorporated Human ion channel protein and polynucleotides encoding the same
US6455568B2 (en) * 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
US6376486B1 (en) * 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
WO2002015902A1 (en) * 2000-08-23 2002-02-28 Merck & Co., Inc. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6613786B2 (en) * 2001-11-02 2003-09-02 Bristol-Myers Squibb Company Thiophenyl triazol-3-one derivatives as smooth muscle relaxants
JP2007520996A (ja) * 2003-01-15 2007-08-02 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 44390、54181、211、5687、884、1405、636、4421、5410、30905、2045、16405、18560、2047、33751、52872、14063、20739、32544、43239、44373、51164、53010、16852、1587、2207、22245、2387、52908、69112、14990、18547、115、579、15985、15625、760、18603、2395、2554、8675、32720、4809、14303、16816、17827、32620、577、619、1423、2158、8263、15402、16209、16386、21165、30911、41897、1643、2543、9626、13231、32409、84260、2882、8203、32678または55053を用いて泌尿器科障害を処置するための方法および組成物
EP1640021A4 (en) * 2003-06-30 2008-01-23 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF HARVESE DISORDERS
JP4977837B2 (ja) * 2003-09-10 2012-07-18 アイカジェン, インコーポレイテッド カリウム・チャネル・モジュレーターとしての縮合環式複素環
AU2006239941A1 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
US7517960B2 (en) * 2006-01-19 2009-04-14 Wyeth Rat KCNQ5 voltage-gated potassium channel

Also Published As

Publication number Publication date
ES2253432T3 (es) 2006-06-01
NZ525301A (en) 2004-10-29
US20050101004A1 (en) 2005-05-12
WO2002032960A3 (en) 2003-04-17
JP2004511516A (ja) 2004-04-15
CY1105353T1 (el) 2010-03-03
IL155090A0 (en) 2003-10-31
US7160684B2 (en) 2007-01-09
TWI287984B (en) 2007-10-11
KR20030040540A (ko) 2003-05-22
AU2002213308A1 (en) 2002-04-29
CA2450467A1 (en) 2002-04-25
CA2450467C (en) 2011-05-24
CN1287781C (zh) 2006-12-06
EP1328550A2 (en) 2003-07-23
MXPA03003339A (es) 2003-06-19
DK1326597T3 (da) 2006-02-13
US6348486B1 (en) 2002-02-19
AR030901A1 (es) 2003-09-03
WO2002032419A3 (en) 2002-08-15
EP1326597A2 (en) 2003-07-16
PL360903A1 (en) 2004-09-20
CN1469739A (zh) 2004-01-21
DE60116352T2 (de) 2006-06-22
WO2002032960A2 (en) 2002-04-25
JP2004529611A (ja) 2004-09-30
CA2425742A1 (en) 2002-04-25
EP1326597B1 (en) 2005-12-28
ATE314061T1 (de) 2006-01-15
HUP0303288A2 (hu) 2004-01-28
WO2002032419A2 (en) 2002-04-25
AU2002211758A1 (en) 2002-04-29
US20060252104A1 (en) 2006-11-09
HK1056514A1 (en) 2004-02-20
DE60116352D1 (de) 2006-02-02
NO20031580L (no) 2003-06-14
BR0114718A (pt) 2003-10-14

Similar Documents

Publication Publication Date Title
NO20031580D0 (no) Fremgangsmåter for modulering av bl¶refunksjonen
DK1181017T3 (da) Metalloproteaseinhibitorer
DE60141776D1 (de) Trokaranordnung
NO20024984D0 (no) Ern¶ringsmoduler
DE59808818D1 (de) Chirurgischer Spreizer
DE50111776D1 (de) Anschwemmfilter
BR7903354Y1 (pt) dispositivo de apresentaÇço.
DE60142401D1 (de) Verbindungsverfahren
MXPA01011760A (es) Compuestos novedosos de difeniletileno.
ES1046206Y (es) Aparato quirurgico.
EP1315423A4 (en) THERMOSTABLE BIOLOGICAL MATRIX
DE60032221D1 (de) Trokarsystem
DE60041783D1 (de) Bremseinheit
NO20022363L (no) Tannimplantatb¶rersammenstilling
ATA4432000A (de) Streugerät
DE50106006D1 (de) Streugerät
EP1307662A4 (en) Brake plate
DK1102012T3 (da) Udluftningsindretning
ITTO20010121U1 (it) Proiettore per veicoli.
ITTO20010073V0 (it) Proiettore per veicoli.
DE50007351D1 (de) Zweischeibenschleuderstreuer
ATA80062000A (de) Spreizvorrichtung
KR20030028487A (ko) 신호 변조
ES1047885Y (es) Aplique luminoso polivalente.
NO20005126D0 (no) FremgangsmÕte for formidling av informasjon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application